Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02152631 · ClinicalTrials.gov registry record · Phase 3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 453
- Enrollment target
- 20
- Study locations
NCT02152631 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 453 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT02152631, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 453 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.
Conditions Studied
Interventions
- DRUG Abemaciclib
- DRUG Erlotinib
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- University of California - San Diego - La Jolla
- Loma Linda University School of Medicine - Loma Linda
- CBCC Global Research, Inc. - Los Angeles
- Central Coast Medical Oncology Corporation - Los Angeles
- Fort Wayne Oncology & Hematology - Los Angeles
- SMO TRIO -Translational Research - Los Angeles
- St. Joseph Heritage Medical Group - Los Angeles
- UCLA Department of Medicine-Hematology/Oncology - Los Angeles
- Cancer Care Associates Medical Group - Los Angeles
- Dignity Health Care Institute - Sacramento
Colorado
- Alegent Immanuel Cancer Center - Englewood
- Jewish Hospital - Englewood
- Oncology Hematology West - Englewood
- SMO Catholic Health Initiatives - Englewood
- St Joseph Cancer Center - Englewood
- St. Francis Medical Center - Englewood
Arkansas
- Highlands Oncology Group - Fayetteville
- St. Bernards Medical Center - Jonesboro
Delaware
- Medical Oncology Hematology Consultants - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 453 participants |
| Start Date | 2014-10-03 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02152631
The ClinicalTrials.gov registry entry for NCT02152631 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 453 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (31% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Abemaciclib is the first listed.
NCT02152631 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Arkansas.
Frequently Asked Questions
What is clinical trial NCT02152631 about?
NCT02152631 is a clinical study titled "A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer". The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.
What is the current status of trial NCT02152631?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 453 participants. The study started on 2014-10-03. Estimated completion is 2026-12.
What conditions does trial NCT02152631 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT02152631?
The interventions under investigation include: Abemaciclib (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT02152631?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02152631 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.